Loading

Next-gen delivery methods – in vivo vs. ex vivo approaches for autologous and allogeneic therapies [Topic TBC]

04 May 2026

16:15 - 17:15

Next Gen Vector Engineering & Delivery

Industry Expert

Matthew Fuller, Vice President - Head of Gene Therapy Research - Ultragenyx